Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 61Neoplasms 35Colorectal Neoplasms 32Neoplasm Metastasis 31Breast Neoplasms 30Prostatic Neoplasms 26Pancreatic Neoplasms 26Ovarian Neoplasms 26Recurrence 25Multiple Myeloma 25Melanoma 23Squamous Cell Carcinoma of Head and Neck 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Triple Negative Breast Neoplasms 17Endometrial Neoplasms 17Lymphoma, Large B-Cell, Diffuse 16Lung Neoplasms 16Glioblastoma 16Lymphoma, Non-Hodgkin 15Leukemia, Myeloid, Acute 14Burkitt Lymphoma 14Stomach Neoplasms 13Small Cell Lung Carcinoma 12Colonic Neoplasms 12Carcinoma, Renal Cell 12Uterine Cervical Neoplasms 11Lymphoma 11Glioma 11Gastrointestinal Neoplasms 11Lymphoma, Follicular 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Non-small Cell Lung Cancer × 30 days × Clear all
NCT05099172 2026-05-13

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Bayer

Phase 1/2 Active not recruiting
370 enrolled 1 FDA
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡